Vivian Fonseca

Datos Biográficos

ID5545007
NOMBREVivian Fonseca
NOMBRESVivian
APELLIDOFonseca
FIRMAFONSECA V
AFILIACIONESSection of Endocrinology, Tulane University Health Sciences Center, New Orleans
ORCID0000-0002-3381-7151
VERIFICADOSí
TOTAL DE OBRAS2
TOTAL DE CITAS0
TOTAL COMO AUTOR2
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2023
AÑO MÁS RECIENTE DE PUBLICACIÓN2026
ÍNDICE H0

  • Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes

    Open AccessJiali Qin, Man Tang et al.ARTICLEFrontiers in Public Health2026

    Background: This study aimed to evaluate the long-term cost-effectiveness of insulin glargine/lixisenatide injection (iGlarLixi) vs. insulin degludec/insulin aspart (IDegAsp) in individuals with poorly controlled type 2 diabetes in China. Methods: This study employed the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model to simulate 20-year clinical and economic outcomes from the perspective of the Chinese healthcare sy…

  • The Impact of Reimbursement for Non–Face-to-Face Chronic Care Management on Comprehensive Metabolic Biomarkers Among Multimorbid Patients With Type 2 Diabetes

    Open AccessYixue Shao, Charles Stoecker et al.ARTICLEMedical Care2023Referencias: 18

    AIMS: We evaluated the impact of reimbursement for non-face-to-face chronic care management (NFFCCM) on comprehensive metabolic risk factors among multimorbid Medicare beneficiaries with type 2 diabetes in Louisiana. MATERIALS AND METHODS: We implemented a propensity score method to obtain comparable treatment (n=1501 with NFFCCM) and control (n=17,524 without NFFCCM) groups. Patients with type 2 diabetes were extracted from the electronic health…